Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies.

Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S ...

Mainz Biomed B.V. (MYNZ) has released an update. Mainz Biomed B.V. has entered into a supplemental agreement with YA II PN, LTD. for a fourth Pre-Paid Advance of $1.5 million, following three ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology ...

Mainz Biomed's collaboration with Thermo Fisher aims to advance mRNA-based colorectal cancer screening technologies. ColoAlert improvements reduce retesting rates, delivering results in 2–3 days ...

CALGARY, Alberta--(BUSINESS WIRE)--Fluid Biomed Inc., a clinical stage medical device company developing lifesaving products for patients suffering from vascular disease, closed an oversubscribed ...